Coombs Test: Direct vs Indirect (DAT vs IAT), and How to Interpret Results

Coombs test (antiglobulin test) is used to detect the presence of ‘incomplete’ Rh antibodies i.e. IgG antibodies capable of sensitizing RBCs but incapable of causing agglutination of RBCs (hemagglutination). The antiglobulin (Coombs) test was introduced by Coombs and colleagues in 1945.

The Coombs test is a specialized agglutination test: it makes otherwise invisible IgG coating of red cells visible by using a second antibody (antihuman globulin) to bridge the cells into clumps. Everything else about the test follows from that one idea.

Anti-Rh antibodies are of IgG type, but they normally do not agglutinate Rh-positive RBCs (RBCs containing Rh antigen) so anti-Rh antibodies are also called incomplete antibodies as opposed to ‘complete’ IgM antibodies, which do agglutinate red cells.

Complete vs. Incomplete Antibodies

Figure: Hemagglutination

Red blood cells contain various antigens on their surface. RBC containing antigens A, B, and AB on its surface are designated as blood groups A, B, and AB respectively. Blood group ‘O’ does not contain both antigen ‘A’ and antigen ‘B’ on its surface. These blood group antigens are carbohydrate molecules. Our immune system usually makes IgM class of antibodies against carbohydrate antigen (as it gets no sufficient signals for class switching). These IgM antibodies (which are pentameric in nature) can bind specific antigens present on the surface of RBCs and can agglutinate RBC. So antibodies against ABO blood group antigens are called complete antibodies.

RBC also contains another antigen on its surface, which is called the ‘Rh’ antigen.  Rh antigens are protein in nature. When a person lacking the Rh antigen (that is, Rh-negative) is exposed to Rh antigen (during a blood transfusion or mother during delivery of children having a positive blood group), his/her immune system makes antibodies against Rh antigen. As this Rh antigen is a protein, its exposure generates IgG (class switching occurs).

IgG antibodies thus formed bind specifically to the Rh antigens present on the surface of RBCs but they become unable to agglutinate RBCs (there is no cross-linking or clumping) perhaps due to the presence of insufficient antigenic determinants (epitope) on the RBCs to permit the antibody to overcome normal electrostatic repulsion that exists among RBCs and/or because of the inherent property of IgG (monomeric form).  So, the antibodies formed against Rh antigens are called incomplete antibodies.

Negative charge on the surface of RBCs prevents them from coming closer than within 20 nm of each other, thus IgG antibodies are unable to cross-link red cells as the Fab arms, even when fully extended, are unable to span this distance.

Coombs reagent

The standard (polyspecific) antiglobulin reagent contains anti-IgG and anti-complement (chiefly anti-C3d). If a polyspecific test is positive, monospecific reagents (anti-IgG alone, anti-C3d alone) are then used to determine whether the red cells are coated by antibody, complement, or both. This distinction matters clinically, as shown below.

Direct Coombs Test

Figure: Direct Coombs Test

The direct Coombs test, also known as the direct antiglobulin test (DAT) uses antibodies directed against human proteins (primarily immunoglobulin G [IgG] and complement [C3]) to detect whether these proteins are attached to the surface of RBCs. This involves the addition of Coombs serum directly to a patient’s washed RBCs.

The occurrence of agglutination means that the patient’s RBCs have been sensitized in vivo by the antibody. Direct Coombs testing is vital for diagnosing autoimmune hemolytic anemias such as;

• hemolytic transfusion reaction,
• hemolytic disease of the fetus and newborn (HDFN) and
• autoimmune hemolytic anemia (AIHA) etc.

Indirect Coombs test

The indirect Coombs test, also known as indirect antiglobulin test (IAT) detects antibodies against human RBCs in the patient’s serum. This involves incubating a patient’s serum with RBCs of a known type and adding Coombs serum. If in vitro sensitization occurs, agglutination will result, which indicates that antibodies are present against the known blood type.

The indirect Coombs test is used in crossmatching before blood transfusions and in prenatal testing of pregnant women.

An indirect antiglobulin crossmatch is performed to assure compatibility of red cell units for transfusion in certain patients by incubating the recipient’s plasma or serum and donor red cells.

Figure: Indirect antiglobulin test (Indirect Coombs Test)

• A. If ‘nonagglutinating’ or ‘incomplete’ antibodies against red blood cell antigens are present in patient’s serum, they will coat the RBCs of the donor but won’t be able to clump them together.  When the coombs reagent (anti-human globulin) reagent is added the antihuman antibodies will bind to the Fc portion of non-agglutinating antibodies (IgG) attached to RBCs causing agglutination of the red cells.
• B: If incomplete antibodies are absent in the patient’s serum: anti-human antibodies won’t be able to attach to RBCs so will be washed away. There will be no agglutination of RBCs.

Procedure

Direct antiglobulin test (DAT). The patient's red cells are washed (to remove unbound serum proteins), then polyspecific antihuman globulin is added. Agglutination means the cells were already coated in vivo with antibody or complement. A positive polyspecific result is followed up with monospecific anti-IgG and anti-C3d to characterize the coating.

Indirect antiglobulin test (IAT). The patient's serum is first incubated with reagent red cells of known antigen type, allowing any antibody in the serum to coat those cells in vitro. The cells are then washed and antihuman globulin is added. Agglutination means the serum contained antibody against the test cells. Washing before adding the reagent is essential in both tests: unwashed cells carry free immunoglobulin that would neutralize the antihuman globulin and cause a false negative.

Interpretation

The key to reading a Coombs test is remembering that agglutination is always the positive result, but what it means depends on which test was run.

A positive DAT means the patient's red cells are coated in vivo. The clinical context and the monospecific pattern narrow the cause:

• Anti-IgG positive suggests warm autoimmune hemolytic anemia, hemolytic disease of the fetus and newborn, or a hemolytic transfusion reaction.
• Anti-C3d positive with anti-IgG negative suggests cold agglutinin disease, where complement rather than persistent IgG is left on the cells.

A positive DAT does not by itself diagnose hemolysis. It must be read alongside evidence of hemolysis (reticulocytosis, raised LDH and indirect bilirubin, low haptoglobin, spherocytes). A positive DAT occurs in a small percentage of healthy donors and hospitalized patients with no hemolysis at all.

A positive IAT means the patient's serum contains an antibody against the test red cells. Its meaning depends on the setting: in crossmatching it signals incompatibility, in antibody screening it flags a clinically significant alloantibody, and in prenatal testing it detects maternal antibody that could cause hemolytic disease of the newborn.

Direct vs indirect: which is which

The names describe how many steps stand between the patient and the antihuman globulin.

Direct tests the patient's cells. The antibody is already on the red cells (it bound in vivo), so you add antihuman globulin directly. One step. Question: are the patient's own red cells already coated?

Indirect tests the patient's serum. The antibody is floating in serum and must first be given red cells to bind (in vitro), and only then is antihuman globulin added. Two steps. Question: does the patient's serum contain antibody that could coat red cells?

How to Remember

Direct tests cells, indirect tests serum. In the direct test the antibody is already stuck to the patient's red cells, so you go straight in with antihuman globulin. In the indirect test the antibody is still in the serum, so you first give it cells to stick to, then add the reagent. Direct = cells, one step. Indirect = serum, two steps.

The reagent is a bridge. Incomplete IgG antibodies coat red cells but cannot pull them together, because red cells repel each other and IgG's arms are too short to span the gap. Antihuman globulin is the bridge: it grabs the Fc tails of two IgG molecules on neighboring cells and clumps them. No bridge, no clumping. That single image explains why the test exists at all.

Key exam facts in one table

Where students get confused

"Direct and indirect, which one uses the patient's serum again?" The most-confused point in serology. Direct tests the patient's cells (antibody already on them). Indirect tests the patient's serum (antibody still floating, needs cells added first). If you fix "direct = cells, indirect = serum," everything else follows.

"A positive direct Coombs means the patient has hemolytic anemia." Not on its own. It means the red cells are coated. Whether that is causing hemolysis needs the clinical picture and hemolysis markers. A positive DAT occurs in some healthy people with no disease.

"Why can't IgG just agglutinate the cells itself?" Because red cells carry a negative surface charge that keeps them about 20 nm apart, and IgG's two arms, even fully extended, cannot span that gap. IgM can (it is huge and pentameric), which is why anti-A and anti-B agglutinate directly but anti-Rh does not. The Coombs reagent supplies the missing bridge.

"Anti-IgG positive versus anti-C3d positive, does it matter?" Yes, and it is a favorite exam point. Warm AIHA is typically anti-IgG positive; cold agglutinin disease is typically anti-C3d positive with anti-IgG negative. The monospecific pattern points to the type of hemolytic anemia.

References

• Murphy, K., & Weaver, C. (2016). Janeway's Immunobiology (9th ed.). Garland Science.
• Punt, J., Stranford, S., Jones, P., & Owen, J. A. (2018). Kuby Immunology (8th ed.). W. H. Freeman.
• Tille, P. M. (2022). Bailey & Scott's Diagnostic Microbiology (15th ed.). Elsevier.
• Zarandona, J. M., & Yazer, M. H. (2006). The role of the Coombs test in evaluating hemolysis in adults. CMAJ, 174(3), 305–307.